文献速递皮肤肿瘤

老年人面部基底细胞癌Mohs显微手术再评估

A critical re-evaluation of Mohs micrographic surgery for a facial basal cell carcinoma in older adults: Should we waive this treatment in certain patients?
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-05-13

本回顾性队列研究纳入1998年11月至2012年12月接受Mohs显微手术(MMS)的207例>75岁面部基底细胞癌(BCC)患者,评估年龄校正Charlson共病指数(aCCI)与生存的关系。中位生存7.85年;aCCI<6组中位生存11.58年,aCCI≥6组3.60年(p<0.001);高aCCI与生存强相关(HR 6.25;95%CI 3.83-10.21)。结论建议决策前评估aCCI,高aCCI者应考虑放弃MMS。

要点

  • >75岁面部BCC患者接受MMS后中位生存7.85年。
  • aCCI≥6组中位生存3.60年,低于aCCI<6组的11.58年(p<0.001)。
  • 高aCCI与生存强相关(HR 6.25;95%CI 3.83-10.21)。

核心结论

  • 临床医生应在决定MMS是否适用于老年面部BCC患者前评估aCCI。
  • 高aCCI提示中位生存期低,即使MMS患者功能状态通常较高。
  • 高aCCI老年患者应放弃MMS,选择其他侵入性更小、费用更低的治疗方案。

研究设计与样本

  • 回顾性队列研究,纳入1998年11月至2012年12月接受MMS的>75岁面部BCC患者207例,评估共病、并发症与生存。

主要发现

  • 中位生存7.85年。
  • aCCI<6组中位生存11.58年 vs aCCI≥6组3.60年(p<0.001)。
  • 高aCCI与生存强相关(HR 6.25;95%CI 3.83-10.21)。
  • 其他特征与生存无关。

临床怎么用

  • 老年面部BCC患者在决定MMS前应评估aCCI。
  • 高aCCI(≥6)患者可考虑放弃MMS,选择其他侵入性更小、费用更低的治疗方案。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin cancer incidences are increasing. Treatment for basal cell carcinomas (BCCs) can be questioned in certain patients. Treatment options are various, but Mohs micrographic surgery (MMS) has the highest cure rate. It is, however, time-consuming and results in high logistical burden and treatment costs for both patients and society. OBJECTIVES: This study critically re-evaluates MMS for facial BCCs in older adults. The main objective is to examine all clinical, tumour and patient characteristics in relation to safety and survival to detect a subgroup in which MMS was not the best choice. The overall aim is to identify characteristics that support clinical decision-making in daily practice. METHODS: Patients that received MMS between November 1998 and December 2012 were included. Only patients >75 years with a facial BCC were withheld for analysis. This is a retrospective cohort study, since evaluating the outcome of MMS in accordance with life expectancy is the main objective. Patient charts were evaluated towards comorbidities, complications and survival. RESULTS: This cohort comprises 207 patients. Median survival was 7.85 years. The age-adjusted Charlson comorbidity index (aCCI) was divided into low/medium scores (aCCI < 6) and high scores (aCCI ≥ 6). Median survival was 11.58 years in the low aCCI group and 3.60 years in the high aCCI group (p < 0.001). There was a very strong association between high aCCI and survival (HR, 6.25; 95% CI, 3.83-10.21). Other characteristics were not associated with survival. CONCLUSIONS: Clinicians should assess the aCCI in older patients presenting with a facial BCC before deciding if MMS is an eligible treatment option. High aCCI has shown to be an indicator for low median survival, even in MMS patients with usually high functional status. MMS should be waived as treatment in older patients with high aCCI scores in favour of other, less intensive and less expensive treatment options.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Van Coile L, Brochez L, Verhaeghe E, et al. A critical re-evaluation of Mohs micrographic surgery for a facial basal cell carcinoma in older adults: Should we waive this treatment in certain patients? J Eur Acad Dermatol Venereol. 2023. PMID: 37147863. doi:10.1111/jdv.19158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。